Pd-l1 (sp 142)

What is PD-L1 (SP 142) test?

The PD-L1 (SP142) test is an immunohistochemistry (IHC) assay that detects PD-L1 protein expression in tumor tissue, using the SP142 antibody clone. It's primarily used to guide immunotherapy decisions in various cancers—especially non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Why consider PD-L1 (SP 142) test?

PD-L1 (SP142) test helps determine whether a patient may benefit from immunotherapy. PD-L1 (SP142) test is specifically validated for Guides Immunotherapy Decisions especially for Atezolizumab (Tecentriq) therapy.

Who should get this PD-L1 (SP 142) test?

The PD-L1 (SP142) immunohistochemistry (IHC) test should be performed in specific cancer patients where PD-L1 expression is required to determine eligibility for treatment with the immunotherapy drug atezolizumab.

• Patients with locally advanced or metastatic TNBC
• Patients with advanced or metastatic NSCLC
• Patients with locally advanced or metastatic urothelial carcinoma

More Information about PD-L1 (SP 142) test

PD-L1 (Programmed Death-Ligand 1) is a protein expressed on tumor cells and immune cells. It binds to PD-1 receptors on T cells and inhibits immune response, allowing tumors to evade detection. Drugs like atezolizumab, nivolumab, and pembrolizumab block this interaction, reactivating immune responses.

OTHER NAMES: Ventana PD‑L1 (SP142) Assay; PD‑L1 IHC SP142; PD‑L1 by IHC (SP142 clone); PD‑L1 (SP142) Ventana.